Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageAmneal Pharmaceuticals, Inc. (the “Company”, “we,” “us,” or “our”) is a diversified, global biopharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines. Our Affordable Medicines segment includes retail generics, injectables, and biosimilars. In our Specialty segment, we offer a portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders.
In the company’s own words · 10-K filed Feb 27, 2026 · SEC EDGAR
Business segments
Q1 2026 · $684.7MThe company’s own SEC segment disclosure.
- Subtotal Therapeutic Classes$133.3M19%
- Distribution Service$89.1M13%
- Central Nervous System$83.4M12%
- Transdermal$74.0M11%
- Government Label$59.9M9%
- Injectable$49.9M7%
- Other (9)$195.0M28%
Amneal Pharmaceuticals, Inc. (AMRX) reported revenue of $723M in Q1 2026 (quarter ended March 31, 2026), up 3.9% from the same quarter a year earlier. That came with a gross margin of 44% and net income of $62M (8.6% of revenue). For the full year FY2025, revenue was $3.02B (+8.0% year on year) and net income $72M. Its largest product in 2026-Q1 was Subtotal Therapeutic Classes at $133M, 19% of the disclosed total, just ahead of Distribution Service at 13%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Drug Manufacturers - Specialty & Generic
Ranks #22 of 28 by Smart Score